Funding history
- $330MSeries B2026-06-24Source: news.google.com ↗
Investors in Ollin Biosciences
Backers from this company's tracked funding rounds.
- TCGX
- ARCH Venture Partners
More Health companies
Recently funded startups in the same category.
Ollin Biosciences is developing treatments for eye diseases, specifically targeting conditions like diabetic macular edema and wet age-related macular degeneration. The company has raised $330 million in Series B funding to support its upcoming Phase 3 trial, making it one of the largest funding rounds for a biotech company in recent years.
Backers from this company's tracked funding rounds.
Recently funded startups in the same category.